Synthetic biology approaches for enhancing safety and specificity of CAR-T cell therapies for solid cancers.
Cytotherapy
; 26(8): 842-857, 2024 Aug.
Article
en En
| MEDLINE
| ID: mdl-38639669
ABSTRACT
CAR-T cell therapies have been successful in treating numerous hematologic malignancies as the T cell can be engineered to target a specific antigen associated with the disease. However, translating CAR-T cell therapies for solid cancers is proving more challenging due to the lack of truly tumor-associated antigens and the high risk of off-target toxicities. To combat this, numerous synthetic biology mechanisms are being incorporated to create safer and more specific CAR-T cells that can be spatiotemporally controlled with increased precision. Here, we seek to summarize and analyze the advancements for CAR-T cell therapies with respect to clinical implementation, from the perspective of synthetic biology and immunology. This review should serve as a resource for further investigation and growth within the field of personalized cellular therapies.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Linfocitos T
/
Inmunoterapia Adoptiva
/
Biología Sintética
/
Receptores Quiméricos de Antígenos
/
Neoplasias
Idioma:
En
Revista:
Cytotherapy
Asunto de la revista:
TERAPEUTICA
Año:
2024
Tipo del documento:
Article